Investor Presentaiton
43
Investor presentation
Full year 2022
Novo Nordisk has 55% of the global GLP-1 market, while GLP-1
penetration of diabetes volume varies across regions
80%
60%
40%
20%
Novo NordiskⓇ
GLP-1 market growth and Novo Nordisk market share
5% of total diabetes prescriptions use a GLP-1 with large
differences across markets
Million scripts
Global: 5%
69%
8
63%
OZEMPİC
semaglutide injection
RYBELSUS
semaglutide tablets
6
58%
55%
4
2
0%
0
Nov
Nov
2017
2019
2022
-NN market share
NN share of growth
EMEA
-Market growth
NN growth
North America
Patient share based on data for the USA, the UK, Germany and France only.
Source: IQVIA MAT value (spot rate), Nov 2022
Region China
11%
2%
2%
4%
2022
Rest of World
GLP-1 share of diabetes prescription
EMEA: Europe, Middle East and Africa; Region China covers Mainland China, Taiwan, and Hong Kong
Source: IQVIA MAT, Nov 2022View entire presentation